澳大利亚和新西兰终末期肾病患者退出治疗的死因分析
该回顾性队列研究基于澳大利亚和新西兰透析移植登记系统,纳入1980-2013年澳大利亚及1988-2012年新西兰的60 823例终末期肾病(ESKD)患者,分析退出治疗后的死亡率及死亡证明中的死因。结果显示退出治疗死亡占ESKD死亡的24%,相关死亡率从1995年的1142/10万人年升至2013年的2706/10万人年;仅20%的退出治疗死亡以肾衰竭为根本死因,18%未提及肾脏病。
要点
- 退出治疗死亡占ESKD全部死亡的24%,相关死亡率自1988年以来增加一倍以上。
- 退出治疗相关死亡率女性及高龄组更高,1995-2006年增幅最大。
- 仅20%退出治疗死亡以肾衰竭为根本死因,18%死亡证明未提及肾脏病。
核心结论
- 退出治疗占ESKD死亡的24%,相关死亡率自1988年以来增加一倍以上。
- 死亡证明中仅20%的退出治疗病例以肾衰竭为根本死因,18%未提及肾脏病。
研究设计与样本
- 回顾性队列研究,纳入澳大利亚1980-2013年及新西兰1988-2012年登记的60 823例ESKD患者。
- 通过数据链接获取澳大利亚国家死亡索引和新西兰死亡收集数据库中的死亡证明死因。
主要发现
- 共8111例退出治疗死亡和26 207例其他死亡,随访381 874人年。
- 退出治疗相关死亡率女性及高龄组更高,1995-2013年从1142/10万人年(95%CI 1064-1226)升至2706/10万人年(95%CI 2498-2932)。
- 三分之一退出治疗死亡发生在治疗模式变更后12个月内。
- 死亡证明中肾衰竭为根本死因者占20%,糖尿病占21%,高血压病占7%,18%未提及肾脏病。
临床怎么用
- 人群数据可补充但不能替代临床数据用于终末期肾病临终服务规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Withdrawal from renal replacement therapy is common in patients with end-stage kidney disease (ESKD), but end-of-life service planning is challenging without population-specific data. We aimed to describe mortality after treatment withdrawal in Australian and New Zealand ESKD patients and evaluate death-certified causes of death. METHODS: We performed a retrospective cohort study on incident patients with ESKD in Australia, 1980-2013, and New Zealand, 1988-2012, from the Australian and New Zealand Dialysis and Transplant registry. We estimated mortality rates (by age, sex, calendar year and country) and summarized withdrawal-related deaths within 12 months of treatment modality change. Certified causes of death were ascertained from data linkage with the Australian National Death Index and New Zealand Mortality Collection database. RESULTS: Of 60 823 patients with ESKD, there were 8111 treatment withdrawal deaths and 26 207 other deaths over 381 874 person-years. Withdrawal-related mortality rates were higher in females and older age groups. Rates increased between 1995 and 2013, from 1142 (95% confidence interval 1064-1226) to 2706/100 000 person-years (95% confidence interval 2498-2932), with the greatest increase in 1995-2006. A third of withdrawal deaths occurred within 12 months of treatment modality change. The national death registers reported kidney failure as the underlying cause of death in 20% of withdrawal cases, with other causes including diabetes (21%) and hypertensive disease (7%). Kidney disease was not mentioned for 18% of withdrawal patients. CONCLUSIONS: Treatment withdrawal represents 24% of ESKD deaths and has more than doubled in rate since 1988. Population data may supplement, but not replace, clinical data for end-of-life kidney-related service planning.
引用
- Khou V, De La Mata NL, Morton RL, et al. Cause of death for people with end-stage kidney disease withdrawing from treatment in Australia and New Zealand. Nephrol Dial Transplant. 2021. PMID: 32750144. doi:10.1093/ndt/gfaa105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。